Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both

New England Journal of Medicine

Volumn 339, Issue 26, 1998, Pages 1889-1895

  El Sadr, Wafaa M ^a,m   Murphy, Robert L ^b   Yurik, Teresa McCabe ^c   Luskin Hawk, Roberta ^e   Cheung, Tony W ^f   Balfour, Henry H ^d   Eng, Robert ^g   Hooton, Thomas M ^h   Kerkering, Thomas M ⁱ   Schutz, Malte ^j   Van Der Horst, Charles D ^k   Hafner, Richard ^l  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c School of Public Health   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e Saint Joseph Hospital   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m HARLEM HOSPITAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATOVAQUONE; COTRIMOXAZOLE; DAPSONE; FOLINIC ACID; PENTAMIDINE; PROTEINASE INHIBITOR; PYRIMETHAMINE; SULFONAMIDE; TRIMETHOPRIM;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG BIOPSY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; TOXOPLASMOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ATOVAQUONE; DAPSONE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; NAPHTHOQUINONES; PNEUMONIA, PNEUMOCYSTIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0032564702     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199812243392604     Document Type: Article

References (19)

1. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994;120:932-44.
2. Chaisson RE, Keruly J, Richraan DD, Moore RD. Pneumocystic prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992;152:2009-13.
3. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
4. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 1992;327:1853-60. [Erratum, N Engl J Med 1993;328:1136.]
5. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995; 20:531-41.
6. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A metaanalysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:177-88.
7. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:104-14.
8. Hughes WT, Gray VL, Gutteridge WE, Latter VS, Pudney M. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1990;34:225-8.
9. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521-7.
10. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
11. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMPSMZ. Clin Infect Dis 1995;20:849-53.
12. Para MF, Dohn M, Frame P, Beckcr S, Finkelstein DL, Walawander A. ACTG 268 trial: gradual initiation of trimethoprim/sulfamethoxazole as a primary prophylaxis for Pneumocystis carinii pneumonia. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997:65. abstract.
13. Leoung G, Stanford J, Giordano M, et al. A randomized, double-blind trial of trimethoprim-sulfamethoxazole dose escalation vs. direct rechallenge in HIV+ persons at risk for P. carinii pneumonia and with prior treatment-limiting rash or fever. In: Addendum to program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:10. abstract.
14. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46(RR-12):1-46.
15. Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS 1993;7:355-9.
16. Chaisson RE, Moore RD. Prevention of opportunistic infections in the era of improved antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:Suppl 1:S14-S22.
17. Murphy R, El-Sadr W, Cheung T, et al. Impact of proteasc inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study. In: Proceedings of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998:113. abstract.
18. Salmon-Ceron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995; 172:656-64. [Erratum, J Infect Dis 1996;173:277.]
19. Chene G, Saillour F, Salmi LR, et al. Effect of dapsone on survival in HIV-infected patients: a meta-analysis. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:269. abstract.